chr3:12582101:> Detail (hg38)
Information
Genome
| Assembly | Position |
|---|---|
| hg19 | chr3:12,623,600-12,705,686 |
| hg38 | chr3:12,582,101-12,664,187 |
HGVS
| Type | Transcript | Protein |
|---|---|---|
Summary
MGeND
| Clinical significance | |
| Variant entry | |
| GWAS entry | |
| Disease area statistics | Show details |
Frequency
[No Data.]
Prediction
[No Data.]
ClinVar
| Clinical Significance | |
| Review star | [No Data.] |
| Show details | |
Links
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
[No Data.]
CIViC
[No Data.]
DisGeNET
| Score | Disease name | Description | Source | Pubmed | Links |
|---|---|---|---|---|---|
| 0.004 | squamous cell carcinoma | NA | BeFree,LHGDN | Detail | |
| <0.001 | Carcinoma, Transitional Cell | NA | BeFree | Detail | |
| 0.120 | Cardiomyopathy, Dilated | NA | BeFree,CTD_human | Detail | |
| 0.125 | hypertrophic cardiomyopathy | Mutations in RAF1 are associated with Noonan syndrome and hypertrophic cardiomyo... | BeFree,CTD_human,LHGDN | 25706034 | Detail |
| 0.004 | colorectal carcinoma | Small interfering RNA (siRNA) screening of 37 KRAS mutant colorectal cancer cell... | BeFree | 25199829 | Detail |
| 0.004 | colorectal carcinoma | Collectively, our study demonstrated that miR-455-RAF1 may represent a new poten... | BeFree | 25355599 | Detail |
| 0.004 | colorectal carcinoma | BRAF-mutant metastatic colorectal cancer (mCRC) forms an aggressive subset of co... | BeFree | 25589621 | Detail |
| 0.004 | colorectal carcinoma | RAF inhibitor combinations represent promising approaches in clinical developmen... | BeFree | 25673644 | Detail |
| 0.004 | colorectal carcinoma | We analyzed the mutation spectra of the PI3K/PTEN/AKT and RAS/RAF/MAPK pathways ... | BeFree | 25920435 | Detail |
| 0.004 | Colorectal Neoplasms | More than half of colorectal tumors harbor activating mutations in RAS/RAF prote... | BeFree,LHGDN | 25322874 | Detail |
| 0.004 | Colorectal Neoplasms | Preclinical data show that reactivation of EGFR signaling occurs in colorectal t... | BeFree,LHGDN | 25589621 | Detail |
| 0.001 | Dengue Fever | NA | BeFree | Detail | |
| <0.001 | Diabetes | NA | BeFree | Detail | |
| <0.001 | diabetes mellitus | NA | BeFree | Detail | |
| <0.001 | diabetic retinopathy | NA | BeFree | Detail | |
| <0.001 | Dwarfism | NA | BeFree | Detail | |
| 0.002 | Dyslexia, Acquired | NA | GAD | Detail | |
| <0.001 | endometriosis | NA | BeFree | Detail | |
| <0.001 | fibrosarcoma | NA | BeFree | Detail | |
| <0.001 | Giant Cell Tumors | NA | BeFree | Detail | |
| 0.001 | glioblastoma | NA | BeFree | Detail | |
| 0.128 | Glioma | NA | BeFree,CTD_human,GAD,LHGDN | Detail | |
| <0.001 | Sensorineural Hearing Loss (disorder) | NA | BeFree | Detail | |
| 0.003 | congenital heart defects | NA | BeFree,GAD | Detail | |
| 0.002 | Cardiomegaly | NA | GAD | Detail | |
| 0.003 | hepatitis B | NA | BeFree,LHGDN | Detail | |
| 0.002 | hepatitis C | NA | BeFree | Detail | |
| 0.002 | Von Hippel-Lindau syndrome | NA | BeFree | Detail | |
| 0.120 | Hyperalgesia | NA | CTD_human | Detail | |
| <0.001 | keratoacanthoma | NA | BeFree | Detail | |
| 0.120 | Kidney Neoplasm | NA | BeFree,CTD_human | Detail | |
| 0.002 | Language Disorders | NA | GAD | Detail | |
| 0.005 | leukemia | We investigated the expression levels of MKRN2 and RAF1 in normal and malignant ... | BeFree,LHGDN | 24675897 | Detail |
| <0.001 | Acute Erythroblastic Leukemia | NA | BeFree | Detail | |
| 0.005 | Leukemia, Myelocytic, Acute | NA | BeFree,LHGDN | Detail | |
| 0.001 | myeloid leukemia | NA | BeFree | Detail | |
| <0.001 | Myeloid Leukemia, Chronic | NA | BeFree | Detail | |
| <0.001 | Leukemia, T-Cell | NA | BeFree | Detail | |
| 0.121 | Liver neoplasms | NA | BeFree,CTD_human | Detail | |
| 0.121 | Lung Neoplasms | NA | BeFree,CTD_human | Detail | |
| <0.001 | Lymphangiectasis | NA | BeFree | Detail | |
| <0.001 | lymphoma | NA | BeFree | Detail | |
| 0.002 | Malignant neoplasm of stomach | NA | BeFree | Detail | |
| <0.001 | multiple myeloma | NA | BeFree | Detail | |
| <0.001 | myasthenia gravis | MAPK1 and RAF1 were responsible for most of this crosstalk (80%), likely reflect... | BeFree | 25705681 | Detail |
| <0.001 | neurofibromatosis 1 | Moving beyond BRAFV600 targeting, a number of other molecular subsets--such as m... | BeFree | 25993155 | Detail |
| 0.384 | Noonan syndrome | Unique cerebrovascular anomalies in Noonan syndrome with RAF1 mutation. | BeFree,CLINVAR,CTD_human,GAD,LHGDN,ORPHANET | 23877478 | Detail |
| 0.384 | Noonan syndrome | Identification of a novel de novo deletion in RAF1 associated with biventricular... | BeFree,CLINVAR,CTD_human,GAD,LHGDN,ORPHANET | 24782337 | Detail |
| 0.384 | Noonan syndrome | Neonatal pulmonary arterial hypertension and Noonan syndrome: two fatal cases wi... | BeFree,CLINVAR,CTD_human,GAD,LHGDN,ORPHANET | 25706034 | Detail |
| 0.001 | osteosarcoma | NA | BeFree | Detail | |
| 0.001 | ovarian carcinoma | NA | BeFree | Detail | |
| 0.003 | Prostatic Neoplasms | NA | LHGDN | Detail | |
| <0.001 | Respiratory Syncytial Virus Infections | NA | BeFree | Detail | |
| <0.001 | retinal degeneration | NA | BeFree | Detail | |
| 0.003 | retinoblastoma | NA | BeFree,LHGDN | Detail | |
| 0.002 | Skin Abnormalities | NA | GAD | Detail | |
| <0.001 | Dermatologic disorders | NA | BeFree | Detail | |
| 0.002 | Thyroid Neoplasm | NA | GAD | Detail | |
| 0.003 | tuberculosis | NA | LHGDN | Detail | |
| <0.001 | Unipolar Depression | NA | BeFree | Detail | |
| <0.001 | Vascular Diseases | These two cases suggest that abnormal activation of the Ras/MAPK pathway may pla... | BeFree | 25706034 | Detail |
| <0.001 | yellow fever | The interferon signaling antagonist function of yellow fever virus NS5 protein i... | BeFree | 25211074 | Detail |
| <0.001 | severe combined immunodeficiency | NA | BeFree | Detail | |
| <0.001 | Li-Fraumeni syndrome | NA | BeFree | Detail | |
| 0.002 | Left Ventricular Hypertrophy | NA | GAD | Detail | |
| 0.002 | Small cell carcinoma of lung | NA | BeFree | Detail | |
| 0.001 | Cutaneous Melanoma | NA | BeFree | Detail | |
| <0.001 | Adenocarcinoma of lung (disorder) | NA | BeFree | Detail | |
| <0.001 | Idiopathic pulmonary hypertension | The RAF1 gene encodes Raf-1 kinase, part of the Ras/mitogen-activated kinase (MA... | BeFree | 25706034 | Detail |
| <0.001 | Congenital anomaly of cerebrovascular system | Unique cerebrovascular anomalies in Noonan syndrome with RAF1 mutation. | BeFree | 23877478 | Detail |
| 0.369 | LEOPARD Syndrome | To date, PTPN11, RAF1, and BRAF have been reported to be causal for NSML. | BeFree,CLINVAR,CTD_human,GAD,LHGDN,ORPHANET | 25423878 | Detail |
| 0.002 | Tumor Progression | Activating mutations of the RAS-RAF-MAPK pathway initiate and sustain the lesion... | BeFree | 25263173 | Detail |
| 0.002 | Medullary carcinoma | NA | GAD | Detail | |
| <0.001 | cholangiocarcinoma | NA | BeFree | Detail | |
| <0.001 | Carcinoma, Large Cell | NA | BeFree | Detail | |
| <0.001 | verrucous carcinoma | NA | BeFree | Detail | |
| <0.001 | Neuroendocrine Tumors | NA | BeFree | Detail | |
| <0.001 | Nevi and Melanomas | NA | BeFree | Detail | |
| <0.001 | uveal melanoma | NA | BeFree | Detail | |
| 0.002 | pancreatic carcinoma | Activating point mutations in the KRAS oncogene are prevalent in pancreatic canc... | BeFree | 24445769 | Detail |
| <0.001 | Gastrointestinal Stromal Tumors | NA | BeFree | Detail | |
| <0.001 | Medullary carcinoma of thyroid | NA | BeFree | Detail | |
| 0.002 | Papillary thyroid carcinoma | GSEA indicated that gene sets related to B-RAF-RAS (P < 0.0001, false discovery ... | BeFree | 25674762 | Detail |
| 0.002 | Malignant neoplasm of lung | NA | BeFree | Detail | |
| <0.001 | Carcinoma, Small Cell | NA | BeFree | Detail | |
| <0.001 | Disease due to Parvoviridae | NA | BeFree | Detail | |
| 0.002 | Metastatic melanoma | NA | BeFree | Detail | |
| <0.001 | Cancer of Head and Neck | Drug-induced RAF dimerization is independent of RAS mutation status and does not... | BeFree | 26053277 | Detail |
| <0.001 | Liver and Intrahepatic Biliary Tract Carcinoma | Novel insight into the molecular pathogenesis of EGF induced liver cancer was ob... | BeFree | 25872475 | Detail |
| <0.001 | Acinar cell carcinoma of pancreas | Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies ... | BeFree | 25266736 | Detail |
| <0.001 | Solid tumour | Dual and triple combination therapies with RAF inhibitors plus other targeted ag... | BeFree | 25847954 | Detail |
| <0.001 | Biventricular hypertrophy | Identification of a novel de novo deletion in RAF1 associated with biventricular... | BeFree | 24782337 | Detail |
| <0.001 | Tumor necrosis | NA | BeFree | Detail | |
| <0.001 | Malignant tumor, fusiform cell type | NA | BeFree | Detail | |
| <0.001 | Carcinoid tumor no ICD-O subtype | NA | BeFree | Detail | |
| 0.121 | pilocytic astrocytoma | NA | BeFree,ORPHANET | Detail | |
| <0.001 | Malignant neoplasm of liver | Novel insight into the molecular pathogenesis of EGF induced liver cancer was ob... | BeFree | 25872475 | Detail |
| 0.002 | Malignant neoplasm of pancreas | Activating point mutations in the KRAS oncogene are prevalent in pancreatic canc... | BeFree | 24445769 | Detail |
| 0.003 | juvenile myelomonocytic leukemia | NA | BeFree,LHGDN | Detail | |
| 0.002 | Malignant neoplasm of prostate | The genetic basis of 50% to 60% of prostate cancer (PCa) is attributable to rear... | BeFree | 25203299 | Detail |
| 0.002 | Malignant neoplasm of prostate | Molecular stratification of prostate cancer (PCa) based on genetic aberrations i... | BeFree | 25809148 | Detail |
| <0.001 | endometrial carcinoma | NA | BeFree | Detail | |
| <0.001 | Squamous cell carcinoma of skin | NA | BeFree | Detail | |
| <0.001 | Malignant glioma | NA | BeFree | Detail | |
| 0.001 | Osteosarcoma of bone | NA | BeFree | Detail | |
| <0.001 | Costello syndrome (disorder) | NA | BeFree | Detail | |
| 0.007 | Carcinogenesis | This Minireview highlights common and divergent features of RAF paralogs, their ... | BeFree | 26000477 | Detail |
| <0.001 | Leukemogenesis | NA | BeFree | Detail | |
| 0.002 | prostate carcinoma | The genetic basis of 50% to 60% of prostate cancer (PCa) is attributable to rear... | BeFree | 25203299 | Detail |
| 0.002 | prostate carcinoma | Molecular stratification of prostate cancer (PCa) based on genetic aberrations i... | BeFree | 25809148 | Detail |
| <0.001 | Refractory cancer | NA | BeFree | Detail | |
| 0.004 | breast carcinoma | NA | BeFree | Detail | |
| 0.002 | Carcinoma of lung | NA | BeFree | Detail | |
| <0.001 | Secondary malignant neoplasm of lymph node | NA | BeFree | Detail | |
| 0.002 | colon carcinoma | NA | BeFree | Detail | |
| 0.001 | stomach carcinoma | NA | BeFree | Detail | |
| <0.001 | Carcinoma of bladder | NA | BeFree | Detail | |
| <0.001 | Malignant neoplasm of kidney | NA | BeFree | Detail | |
| <0.001 | malignant peripheral nerve sheath tumor | NA | BeFree | Detail | |
| <0.001 | Rhabdoid Tumor of the Kidney | NA | BeFree | Detail | |
| <0.001 | Philadelphia chromosome positive | NA | BeFree | Detail | |
| <0.001 | Advanced cancer | Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 ... | BeFree | 24947927 | Detail |
| <0.001 | Cardiomyopathies | NA | BeFree | Detail | |
| 0.008 | ovarian neoplasm | NA | LHGDN | Detail | |
| <0.001 | Femoral artery occlusion | NA | BeFree | Detail | |
| 0.001 | Malignant neoplasm of ovary | NA | BeFree | Detail | |
| <0.001 | Squamous cell carcinoma of the head and neck | One potential therapeutic target for HNSCC is the RAS/RAF/MEK/ERK cascade, which... | BeFree | 26053277 | Detail |
| 0.001 | sarcoma | NA | BeFree | Detail | |
| <0.001 | major depressive disorder | NA | BeFree | Detail | |
| 0.002 | Cardio-facio-cutaneous syndrome | NA | BeFree | Detail | |
| <0.001 | Single tumor | NA | BeFree | Detail | |
| <0.001 | Multiple lentigines | NA | BeFree | Detail | |
| <0.001 | Hereditary Nonpolyposis Colorectal Cancer | NA | BeFree | Detail | |
| <0.001 | Mucinous Neoplasm | NA | BeFree | Detail | |
| <0.001 | pancreatic ductal adenocarcinoma | NA | BeFree | Detail | |
| <0.001 | Treatment related acute myeloid leukaemia | NA | BeFree | Detail | |
| <0.001 | Thymic Lymphoma | NA | BeFree | Detail | |
| 0.120 | Cardiac Hypertrophy | NA | GWASCAT | Detail | |
| 0.121 | Mammary Neoplasms | NA | BeFree,CTD_human | Detail | |
| <0.001 | Benign Struma Ovarii | NA | BeFree | Detail | |
| <0.001 | Breast Cancer Model | NA | BeFree | Detail | |
| <0.001 | Hepatocarcinogenesis | Ras and Raf gene mutations are rare events in human hepatocarcinogenesis in cont... | BeFree | 25832714 | Detail |
| <0.001 | Cancer Cell Growth | NA | BeFree | Detail | |
| <0.001 | Tumor Angiogenesis | NA | BeFree | Detail | |
| 0.004 | colorectal cancer | Small interfering RNA (siRNA) screening of 37 KRAS mutant colorectal cancer cell... | BeFree | 25199829 | Detail |
| 0.004 | colorectal cancer | BRAF-mutant metastatic colorectal cancer (mCRC) forms an aggressive subset of co... | BeFree | 25589621 | Detail |
| 0.004 | colorectal cancer | RAF inhibitor combinations represent promising approaches in clinical developmen... | BeFree | 25673644 | Detail |
| 0.004 | colorectal cancer | We analyzed the mutation spectra of the PI3K/PTEN/AKT and RAS/RAF/MAPK pathways ... | BeFree | 25920435 | Detail |
| <0.001 | Non-Malignant Ascites Adverse Event | NA | BeFree | Detail | |
| <0.001 | Glioblastoma multiforme | NA | BeFree | Detail | |
| <0.001 | TUBEROUS SCLEROSIS 2 (disorder) | NA | BeFree | Detail | |
| <0.001 | Nonmedullary thyroid carcinoma, with or without cell oxyphilia | NA | BeFree | Detail | |
| <0.001 | PHOTOPAROXYSMAL RESPONSE 1 | NA | BeFree | Detail | |
| <0.001 | Photoreceptor degeneration | NA | BeFree | Detail | |
| <0.001 | Urothelial Carcinoma | NA | BeFree | Detail | |
| 0.003 | liver carcinoma | Sorafenib increases survival of patients with advanced hepatocellular carcinoma ... | BeFree | 25862849 | Detail |
| 0.003 | liver carcinoma | Sorafenib is a small molecule that blocks the activation of C-RAF, B-RAF, c-KIT,... | BeFree | 26237499 | Detail |
| <0.001 | Pulmonary arterial hypertension | The RAF1 gene encodes Raf-1 kinase, part of the Ras/mitogen-activated kinase (MA... | BeFree | 25706034 | Detail |
| <0.001 | Bisphosphonate-associated osteonecrosis | NA | BeFree | Detail | |
| 0.003 | Infection | NA | LHGDN | Detail | |
| <0.001 | Pulmonary hypertension, primary, 1, with hereditary hemorrhagic telangiectasia | The RAF1 gene encodes Raf-1 kinase, part of the Ras/mitogen-activated kinase (MA... | BeFree | 25706034 | Detail |
| 0.120 | CARDIOMYOPATHY, DILATED, 1NN | NA | UNIPROT | Detail | |
| 0.007 | adenocarcinoma | NA | BeFree,LHGDN | Detail | |
| <0.001 | adenoma | NA | BeFree | Detail | |
| 0.003 | Alzheimer's disease | NA | LHGDN | Detail | |
| <0.001 | Anaplasia | NA | BeFree | Detail | |
| 0.002 | Cardiac arrhythmia | NA | GAD | Detail | |
| <0.001 | rheumatoid arthritis | NA | BeFree | Detail | |
| 0.002 | Articulation Disorders | NA | GAD | Detail | |
| <0.001 | asthma | NA | BeFree | Detail | |
| <0.001 | Astrocytoma | NA | BeFree | Detail | |
| 0.002 | colon carcinoma | DUSP2 rs1724120 [hazard rate ratio (HRR) = 0.72, 95%CI = 0.54, 0.96; AA versus G... | BeFree | 23027623 | Detail |
| 0.002 | Malignant tumor of colon | DUSP2 rs1724120 [hazard rate ratio (HRR) = 0.72, 95%CI = 0.54, 0.96; AA versus G... | BeFree | 23027623 | Detail |
| <0.001 | Rectal Carcinoma | DUSP2 rs1724120 [hazard rate ratio (HRR) = 0.72, 95%CI = 0.54, 0.96; AA versus G... | BeFree | 23027623 | Detail |
| <0.001 | Malignant neoplasm of urinary bladder | NA | BeFree | Detail | |
| <0.001 | Blast Phase | NA | BeFree | Detail | |
| 0.001 | Brain Neoplasms | NA | BeFree | Detail | |
| 0.004 | Malignant neoplasm of breast | NA | BeFree | Detail | |
| 0.009 | Carcinoid Tumor | NA | BeFree,LHGDN | Detail | |
| 0.002 | Malignant tumor of colon | NA | BeFree | Detail | |
| <0.001 | Rectal Carcinoma | NA | BeFree | Detail | |
| <0.001 | Malignant neoplasm of skin | NA | BeFree | Detail | |
| 0.001 | Malignant neoplasm of thyroid | However, the de novo expression and clinical implications of COT in papillary th... | BeFree | 25674762 | Detail |
| 0.122 | Non-small cell lung carcinoma | Consistent with our in vitro studies, intraperitoneal application of DACE signif... | BeFree,CTD_human | 25674792 | Detail |
| <0.001 | renal cell carcinoma | NA | BeFree | Detail |
Annotation
Annotations
| Descrption | Source | Links |
|---|---|---|
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Mutations in RAF1 are associated with Noonan syndrome and hypertrophic cardiomyopathy. | DisGeNET | Detail |
| Small interfering RNA (siRNA) screening of 37 KRAS mutant colorectal cancer cell lines showed that R... | DisGeNET | Detail |
| Collectively, our study demonstrated that miR-455-RAF1 may represent a new potential therapeutic tar... | DisGeNET | Detail |
| BRAF-mutant metastatic colorectal cancer (mCRC) forms an aggressive subset of colorectal cancer with... | DisGeNET | Detail |
| RAF inhibitor combinations represent promising approaches in clinical development for BRAF-mutant co... | DisGeNET | Detail |
| We analyzed the mutation spectra of the PI3K/PTEN/AKT and RAS/RAF/MAPK pathways in colorectal cancer... | DisGeNET | Detail |
| More than half of colorectal tumors harbor activating mutations in RAS/RAF proteins. | DisGeNET | Detail |
| Preclinical data show that reactivation of EGFR signaling occurs in colorectal tumor cells treated w... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| We investigated the expression levels of MKRN2 and RAF1 in normal and malignant hematopoietic cells,... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| MAPK1 and RAF1 were responsible for most of this crosstalk (80%), likely reflecting their central ro... | DisGeNET | Detail |
| Moving beyond BRAFV600 targeting, a number of other molecular subsets--such as mutations in MEK, NRA... | DisGeNET | Detail |
| Unique cerebrovascular anomalies in Noonan syndrome with RAF1 mutation. | DisGeNET | Detail |
| Identification of a novel de novo deletion in RAF1 associated with biventricular hypertrophy in Noon... | DisGeNET | Detail |
| Neonatal pulmonary arterial hypertension and Noonan syndrome: two fatal cases with a specific RAF1 m... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| These two cases suggest that abnormal activation of the Ras/MAPK pathway may play a significant role... | DisGeNET | Detail |
| The interferon signaling antagonist function of yellow fever virus NS5 protein is activated by type ... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| The RAF1 gene encodes Raf-1 kinase, part of the Ras/mitogen-activated kinase (MAPK) signaling pathwa... | DisGeNET | Detail |
| Unique cerebrovascular anomalies in Noonan syndrome with RAF1 mutation. | DisGeNET | Detail |
| To date, PTPN11, RAF1, and BRAF have been reported to be causal for NSML. | DisGeNET | Detail |
| Activating mutations of the RAS-RAF-MAPK pathway initiate and sustain the lesions of the SP, and CpG... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Activating point mutations in the KRAS oncogene are prevalent in pancreatic cancer and result in the... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| GSEA indicated that gene sets related to B-RAF-RAS (P < 0.0001, false discovery rate [FDR] q-value =... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Drug-induced RAF dimerization is independent of RAS mutation status and does not lead to universal M... | DisGeNET | Detail |
| Novel insight into the molecular pathogenesis of EGF induced liver cancer was obtained and among the... | DisGeNET | Detail |
| Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusion... | DisGeNET | Detail |
| Dual and triple combination therapies with RAF inhibitors plus other targeted agents have demonstrat... | DisGeNET | Detail |
| Identification of a novel de novo deletion in RAF1 associated with biventricular hypertrophy in Noon... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Novel insight into the molecular pathogenesis of EGF induced liver cancer was obtained and among the... | DisGeNET | Detail |
| Activating point mutations in the KRAS oncogene are prevalent in pancreatic cancer and result in the... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| The genetic basis of 50% to 60% of prostate cancer (PCa) is attributable to rearrangements in E26 tr... | DisGeNET | Detail |
| Molecular stratification of prostate cancer (PCa) based on genetic aberrations including ETS or RAF ... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| This Minireview highlights common and divergent features of RAF paralogs, their signaling outputs, a... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| The genetic basis of 50% to 60% of prostate cancer (PCa) is attributable to rearrangements in E26 tr... | DisGeNET | Detail |
| Molecular stratification of prostate cancer (PCa) based on genetic aberrations including ETS or RAF ... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selec... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| One potential therapeutic target for HNSCC is the RAS/RAF/MEK/ERK cascade, which is one of the major... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Ras and Raf gene mutations are rare events in human hepatocarcinogenesis in contrast to experimental... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Small interfering RNA (siRNA) screening of 37 KRAS mutant colorectal cancer cell lines showed that R... | DisGeNET | Detail |
| BRAF-mutant metastatic colorectal cancer (mCRC) forms an aggressive subset of colorectal cancer with... | DisGeNET | Detail |
| RAF inhibitor combinations represent promising approaches in clinical development for BRAF-mutant co... | DisGeNET | Detail |
| We analyzed the mutation spectra of the PI3K/PTEN/AKT and RAS/RAF/MAPK pathways in colorectal cancer... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Sorafenib increases survival of patients with advanced hepatocellular carcinoma (HCC) by inhibiting ... | DisGeNET | Detail |
| Sorafenib is a small molecule that blocks the activation of C-RAF, B-RAF, c-KIT, FLT-3, RET, VEGFR-2... | DisGeNET | Detail |
| The RAF1 gene encodes Raf-1 kinase, part of the Ras/mitogen-activated kinase (MAPK) signaling pathwa... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| The RAF1 gene encodes Raf-1 kinase, part of the Ras/mitogen-activated kinase (MAPK) signaling pathwa... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| DUSP2 rs1724120 [hazard rate ratio (HRR) = 0.72, 95%CI = 0.54, 0.96; AA versus GG/GA), MAP3K10 rs112... | DisGeNET | Detail |
| DUSP2 rs1724120 [hazard rate ratio (HRR) = 0.72, 95%CI = 0.54, 0.96; AA versus GG/GA), MAP3K10 rs112... | DisGeNET | Detail |
| DUSP2 rs1724120 [hazard rate ratio (HRR) = 0.72, 95%CI = 0.54, 0.96; AA versus GG/GA), MAP3K10 rs112... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| However, the de novo expression and clinical implications of COT in papillary thyroid cancer (PTC) h... | DisGeNET | Detail |
| Consistent with our in vitro studies, intraperitoneal application of DACE significantly suppressed t... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
Overlapped Transcript Coordinates
| Gene | Transcript ID | Exon Number | Chromosome | Start | Stop | Type | Amino Mutation | Transcript Position | Links |
|---|
Overlapped Transcript
| Gene | Transcript ID | Chromosome | Start | Stop | Links |
|---|
- Gene
- -
- dbSNP
- rs112956 dbSNP
- Genome
- hg38
- Position
- chr3:12,582,101-12,664,187
- Variant Type
- snv
Genome browser